TIGERMED (03347) has announced that Hangzhou Tigermed Consulting Co.,Ltd. held its 25th meeting of the fifth board of directors on May 13, 2026, where the proposal for a share repurchase plan was reviewed and approved. According to the buyback scheme, the company intends to use its own funds or raised capital to repurchase a portion of its A-shares through centralized bidding or other methods permitted by laws and regulations. The repurchased shares are planned for subsequent equity incentive plans, employee stock ownership, or cancellation to reduce registered capital.

The total amount for this share repurchase will be no less than RMB 500 million and no more than RMB 1 billion, with a repurchase price not exceeding RMB 60.00 per share. The actual repurchase amount will be based on the funds used upon completion of the implementation. The execution period for this repurchase is within 12 months from the date the share repurchase plan is approved by the shareholders' meeting.

Recently, the company received a loan commitment letter issued by China Merchants Bank Co., Ltd., Hangzhou Branch. The main terms are as follows: 1. Loan amount: not exceeding RMB 900 million, which is no more than 90% of the upper limit of the repurchase amount; 2. Loan term: not exceeding 36 months; 3. Loan purpose: specifically for repurchasing shares of Hangzhou Tigermed Consulting Co.,Ltd.

The total actual loan amount obtained by the company will not exceed the upper limit of this repurchase plan, with specific loan details subject to the loan contract signed by both parties. This special loan for the repurchase must comply with requirements such as the "Notice on Matters Related to the Establishment of Stock Repurchase and Increase Loan Relending by the People's Bank of China, the National Financial Regulatory Administration, and the China Securities Regulatory Commission," and must meet the loan policies, standards, and procedures established by the bank in accordance with relevant regulations.